Physician
Pediatrics
Dr. Francisco J. Cervantes, MD
|
|
Give Review
Francisco Cervantes works in the field of Pediatrics. He went to medical school at Medical College of Georgia. Francisco Cervantes is a published doctor and has 102 publications published. The lastest was: 'Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients.'
Publications
- Immobilization of metal-humic acid complexes in anaerobic granular sludge for their application as solid-phase redox mediators in the biotransformation of iopromide in...
- Immobilization of biogenic Pd(0) in anaerobic granular sludge for the biotransformation of recalcitrant halogenated pollutants in UASB reactors.
- Graphene oxide as electron shuttle for increased redox conversion of contaminants under methanogenic and sulfate-reducing conditions.
- Ruxolitinib and survival improvement in patients with myelofibrosis.
- Role of calreticulin mutations in the etiological diagnosis of splanchnic vein thrombosis.
- Use of the Functional Assessment of Cancer Therapy-Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia.
- Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
- Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system amo...
- Assessing the impact of alumina nanoparticles in an anaerobic consortium: methanogenic and humus reducing activity.
- Anaerobic degradation of benzene by enriched consortia with humic acids as terminal electron acceptors.
- Colour removal of dyes from synthetic and real textile wastewaters in one- and two-stage anaerobic systems.
- Immobilized redox mediators on anion exchange resins and their role on the reductive decolorization of azo dyes.
- Azo dye reduction by mesophilic and thermophilic anaerobic consortia.
- Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia.
- International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatm...
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
- Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
- Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
- Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: ...
- Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Co...
- Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
- Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
- Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia.
- Portal hypertension secondary to myelofibrosis: a study of three cases.
- Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
- Modern management of myelofibrosis.
- Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.
- Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).
- Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients.
- TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy.
- Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-in...
- Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera.
- The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha.
- Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-...
- Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
- Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients.
- Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation.
- Idiopathic myelofibrosis associated with ulcerative colitis.
- Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
- Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
- Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia.
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
- Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients.
- Idiopathic myelofibrosis associated with classic polyarteritis nodosa.
- Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile a...
- Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
- Idiopathic myelofibrosis associated with primary biliary cirrhosis.
- Survival after progression in patients with follicular lymphoma: analysis of prognostic factors.
- Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis.
- Simultaneous occurrence of multiple myeloma and chronic myeloid leukemia.
- Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia.
- Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients.
- Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
- [Gastric adenocarcinoma associated with Hodgkin''s disease with infiltration of the tonsils and gastric serous membrane].
- [Prognostic studies and current trends in the treatment of chronic myeloid leukemia].
- [Immunoblastic sarcoma associated with dermatitis herpetiformis].
- [Clinico-biological expression of chronic granulocytic leukemia in the diagnostic phase and its prognostic significance].
- Acute myeloblastic leukaemia presenting with superior vena cava syndrome due to mediastinal mass.
- [Treatment of Hodgkin''s disease with ABVD].
- Mathematical models of synaptic plasticity: I. Posttetanic potentiation.
- Mathematical model of synaptic plasticity: III. Heterosynaptic changes.
- Mathematical model of synaptic plasticity: II. Habituation.
- Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.
- Influence of ammonium on the performance of a denitrifying culture under heterotrophic conditions.
- Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.
- Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis.
- A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
- Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
- Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.
- Induction of tolerance in renal transplantation using splenic transplantation: experimental study in a canine model.
- What are RBC-transfusion-dependence and -independence?
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Gr...
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
- IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis.
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
- [Chronic myelogenous leukaemia. Report of a series of 207 patients].
- [Essential thrombocythemia developing into acute leukemia].
- Prognostic discrimination in "good-risk" chronic granulocytic leukemia.
- Iron stores in chronic granulocytic leukaemia at presentation.
- [Mediastinal tumor in a patient with acute myeloblastic leukosis].
- [Serum muramidase activity in chronic myeloid leukemia].
- [Monoclonal origin of chronic myeloproliferative syndromes].
- [Osteolytic lesions in idiopathic myelofibrosis: presentation of 2 cases].
- [Surgical treatment of the ductus arteriosus in premature infants].
- [Multiple myeloma: description of a series of 170 cases].
- Myeloproliferative disease in two young siblings.
- Thrombocytosis in quiescent chronic granulocytic leukaemia after vincristine and 6-mercaptopurine therapy.
- Tumour lysis syndrome with hypocälcaemia in accelerated chronic granulocytic leukaemia.
- [Blast crisis mimicking acute leukaemia as first manifestations of chronic myelogenous leukaemia. Report of three cases (author''s transl)].
- Prognostic significance of cytogenetical studies in chronic granulocytic leukaemia.
- A multivariate analysis of prognostic factors in chronic myeloid leukemia.
- [Allogenic bone-marrow transplantation in severe marrow aplasia. Analysis of 12 consecutive cases (author''s transl)].
- [Bone marrow transplantation in acute leukaemia (author''s transl)].
- Liver disease in brucellosis. A clinical and pathological study of 40 cases.
- [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma].
- Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients.
- Coupling between anammox and autotrophic denitrification for simultaneous removal of ammonium and sulfide by enriched marine sediments.
Doctors Specialties
- Neonatal Medicine
- Pediatrics
Accepted Insurances
Education
-
California Pacific Medical Center - California Campus -
Medical College of Georgia -
UMDNJ-University Hospital -
Universidad Autonoma de Nuevo Leon
Drug Facts
| NPI NUMBER | 1669480752 | |
| NPPES Provider LastName | CERVANTES | |
| NPPES Provider FirstName | FRANCISCO | |
| NPPES Provider ZIPCode | 782502562 | |
| NPPES Provider State | TX | |
| Specialty Description | Family Practice | |
| Total Claim Count | 1342.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 25.0 | |
| Percent Opioid Claims | 1.86 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669480752 |
| Last Name Of The Provider | CERVANTES |
| First Name Of The Provider | FRANCISCO |
| View All |
Similar Doctors
|
|
Dr. Amando F. Garza, MD |
|
|
Dr. Roberto J. Villegas Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca Uribe-Garza, MD |
|
|
Dr. Jose L. Berlioz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hector M. Cantu, MD |
|
|
Dr. Patricia E. Cavazos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane C. Unzeitig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan L. Recto, MD |
|
|
Dr. Sara E. Campos, MD
This Doctor is OpenDoctor Recommended.
|